Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports [4]

Acta Oncologica

Volumn 45, Issue 8, 2006, Pages 1137-1138

  Nielsen, Dorte L ^a   Pfeiffer, Per ^b   Jensen, Benny Vittrup ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CETUXIMAB; CLEMASTINE; IRINOTECAN; OXALIPLATIN; PREDNISOLONE;

ADULT; AGED; BRADYCARDIA; CASE REPORT; COLORECTAL CANCER; CONSCIOUSNESS DISORDER; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; HUMAN; HYPOTENSION; LETTER; MALE; MASTALGIA; METASTASIS; PRIORITY JOURNAL; TACHYCARDIA; TREMOR; URTICARIA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; RETREATMENT;

EID: 33751308621     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600871764     Document Type: Letter

References (2)

1. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santaro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
2. Wong S-F. Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorecal cancer. Clin Ther 2005;27:684-94.